Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05079971
Other study ID # A 096043
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date December 2024

Study information

Verified date August 2023
Source Cambridge University Hospitals NHS Foundation Trust
Contact Ronit M Pressler, Phd MD MRCPCH
Phone 07737333607
Email r.pressler@ucl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current project undertakes a prospective multicentre randomised controlled trial to evaluate whether full or continuous electroencephalography (cEEG) is superior to amplitude-integrated electroencephalography (aEEG) in the real time evaluation and diagnosis of neonatal seizures and in reducing time to treatment. At-risk new-born infants will be recruited on the participating neonatal intensive care units (NICUs) by trained specialist staff and will have 24 hours of EEG monitoring.


Description:

Seizures are the most common neurological emergency in the neonatal period, affecting over 2000 infants per year in the UK. Although neonatal seizures usually result from acute brain insults, about 10-15% represent genetic forms of epilepsy which are often diagnosed late, thus limiting the timely use of targeted therapies. Lack or delayed initiation of treatment results in a high seizure burden which is independently associated with worse clinical outcomes. Diagnosing neonatal seizures is challenging because most have only subtle or no clinical manifestation. The gold standard for seizure detection is continuous electroencephalography (cEEG). cEEG can assist with establish the aetiology of seizures, and their management. However, this capability is lacking in most neonatal intensive care units (NICU) due to lack of on-site specialist support. The more common amplitude-integrated EEG (aEEG) uses a limited number of electrodes and is easier to apply and interpret but has been shown to miss a significant number of seizures. It is unclear how often seizure treatment is missed or delayed due to lack of cEEG access. Although studies have compared the diagnostic value of aEEG and cEEG retrospectively, the measured sensitivity of aEEG ranges widely (25-85%), likely due to poor design (retrospective, lack of adequate control group, no power calculations). The current project undertakes a prospective multicentre randomised controlled trial to evaluate whether cEEG is superior to aEEG in the real time evaluation and diagnosis of neonatal seizures and in reducing time to treatment. At-risk neonates will be recruited on the NICU by trained specialist staff and will have 24 hours of EEG monitoring.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 32 Weeks and older
Eligibility Inclusion Criteria: 1. Term or preterm neonate, born at post-menstrual age (PMA) 32-44 weeks; 2. And at least one of the following: (2.1) Neonate with any clinical event suspicious of seizures (2.2) Neonate at high-risk of seizures with confirmed or suspected: (2.2.1) Hypoxic ischaemic encephalopathy (moderate to severe, or deemed eligible for therapeutic hypothermia) (2.2.2) Cerebral vascular insult (e.g., perinatal arterial ischaemic stroke, cerebral venous sinus thrombus) (2.2.3) Meningitis / encephalitis - Inflammatory (2.2.4) Inborn error of metabolism (2.2.5) Brain malformation (2.2.6) Large intraventricular haemorrhage (III-IV) 3. Infant is up to 28 days of age 4. Written informed parental consent can be obtained. Exclusion Criteria: 1. No parental consent 2. Poor prognosis of immediate survival 3. Any contraindication to perform EEG (e.g. structural pathologies interfering with EEG electrode placement, such as cephalohematoma or subgaleal haemorrhage). 4. Infants born at less than 31+6 weeks PMA and infants who are or are suspected to be experiencing or are at high-risk of seizures when aged 29 days or older.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology
In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.

Locations

Country Name City State
United Kingdom Cambridge University Hospitals NHS Foundation Trust Cambridge

Sponsors (6)

Lead Sponsor Collaborator
Cambridge University Hospitals NHS Foundation Trust Guy's and St Thomas' NHS Foundation Trust, Infant, University College Cork, Ireland, Luton and Dunstable Hospital NHS Foundation Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (6)

Boylan GB, Kharoshankaya L, Mathieson SR. Diagnosis of seizures and encephalopathy using conventional EEG and amplitude integrated EEG. Handb Clin Neurol. 2019;162:363-400. doi: 10.1016/B978-0-444-64029-1.00018-7. — View Citation

Gossling L, Alix JJP, Stavroulakis T, Hart AR. Investigating and managing neonatal seizures in the UK: an explanatory sequential mixed methods approach. BMC Pediatr. 2020 Jan 28;20(1):36. doi: 10.1186/s12887-020-1918-4. — View Citation

Malone A, Ryan CA, Fitzgerald A, Burgoyne L, Connolly S, Boylan GB. Interobserver agreement in neonatal seizure identification. Epilepsia. 2009 Sep;50(9):2097-101. doi: 10.1111/j.1528-1167.2009.02132.x. Epub 2009 Jun 1. — View Citation

Pellegrin S, Munoz FM, Padula M, Heath PT, Meller L, Top K, Wilmshurst J, Wiznitzer M, Das MK, Hahn CD, Kucuku M, Oleske J, Vinayan KP, Yozawitz E, Aneja S, Bhat N, Boylan G, Sesay S, Shrestha A, Soul JS, Tagbo B, Joshi J, Soe A, Maltezou HC, Gidudu J, Kochhar S, Pressler RM; Brighton Collaboration Neonatal Seizures Working Group. Neonatal seizures: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2019 Dec 10;37(52):7596-7609. doi: 10.1016/j.vaccine.2019.05.031. No abstract available. — View Citation

Pinchefsky EF, Hahn CD. Outcomes following electrographic seizures and electrographic status epilepticus in the pediatric and neonatal ICUs. Curr Opin Neurol. 2017 Apr;30(2):156-164. doi: 10.1097/WCO.0000000000000425. — View Citation

Rakshasbhuvankar A, Paul S, Nagarajan L, Ghosh S, Rao S. Amplitude-integrated EEG for detection of neonatal seizures: a systematic review. Seizure. 2015 Dec;33:90-8. doi: 10.1016/j.seizure.2015.09.014. Epub 2015 Sep 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Seizure detection yield of aEEG compared to full EEG The primary outcome measure for the study is the difference in the number of correctly identified seizures by NICU staff in real time with (full EEG) or without (aEEG only) the support of clinical neurophysiology. Each participant will be assessed in Group A (aEEG review only) or Group B (a+cEEG) for 24 hours.
Secondary Time from first recorded seizure to first recognised seizure and to treatment. Their time to treatment and time to discharge will also be noted. Each participant's seizure burden, treatment and discharge timelines will be recorded up until their discharge from the hospital, or for up to 6 months, whichever came first.
Secondary Number of false positive seizure detections clinically and/or by aEEG Followed until their discharge from hospital, or for up to 6 months, whichever came first.
Secondary Off-line seizure burden (min/hr) detected by aEEG vs detected by cEEG Followed until their discharge from hospital, or for up to 6 months, whichever came first.
Secondary Parental and staff acceptance of EEG monitoring (combined cohort) using questionnaire. Parents may fill in the questionnaire online after their infant's discharge from hospital, the questionnaire will take a maximum of 10 minutes to complete.
See also
  Status Clinical Trial Phase
Terminated NCT01089504 - Prophylactic Phenobarbital After Neonatal Seizures Phase 4
Terminated NCT02550028 - Levetiracetam Treatment of Neonatal Seizures Phase 1/Phase 2
Completed NCT02789176 - Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study
Not yet recruiting NCT02602015 - Levetiracetam Treatment of Neonatal Seizures Phase 1/Phase 2
Terminated NCT01475656 - Efficacy of Keppra for Neonatal Seizures N/A
Recruiting NCT03107507 - Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG Phase 4
Completed NCT01720667 - Efficacy of Intravenous Levetiracetam in Neonatal Seizures Phase 1/Phase 2
Completed NCT02229123 - Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study Phase 2
Completed NCT01434225 - NEMO1:NEonatal Seizure Using Medication Off-patent Phase 1/Phase 2
Completed NCT02160171 - ANSeR- The Algorithm for Neonatal Seizure Recognition Study N/A